Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neovasc raises C$2 million in private placement
The proceeds of the offering will primarily be used to complete the company’s CE Mark application for the Neovasc Reducer product, a stent for the treatment of refractory
The proceeds of the offering will primarily be used to complete the company’s CE Mark application for the Neovasc Reducer product, a stent for the treatment of refractory
The Pfizer/ University College London (UCL) collaboration brings together the pioneering work of university researchers in the field of cell-based therapies and Pfizer’s expertise in the design and
According to Covidien, the Duet TRS reload offers preloaded tissue reinforcement on the Endo GIA universal range of laparoscopic staplers. The reinforcement material is a synthetic absorbable polymer
MediciNova and the Hercules Market of the Osaka Securities Exchange have reported final results from its Phase II clinical trial evaluating MN-221 at planned escalating doses of 240
The Perlegen intellectual property includes gene variants on chromosome 9p21 linked to increased risk of cardiovascular disease, especially in diabetic patients with poor glycemic control. The licensing agreement
According to ALR Technologies, the ALRT Health-E-Connect system is a communication tool for patients to provide ongoing diagnostic and adherence data to their physicians. Information provided by the
Maryland-based company Sanaria, with support from the PATH Malaria Vaccine Initiative, has initiated a Phase I clinical trial of its malaria vaccine candidate. Unlike other malaria vaccine candidates,
According to Quick-Med Technologies, Nimbus is a next-generation antimicrobial technology that is non-leaching, non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. Ladd Greeno,
According to ApaTech, the results from three new studies show that Actifuse has the potential to be as clinically effective as ICBG, without the problems associated with the
BioFocus DPI will utilize Cellectricon’s DynaflowHT, a fully automated patch clamp (APC) system, to further increase its electrophysiology-based screening capacity, particularly for fast ligand-gated ion channels, said Cellectricon.